BOLT Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Bolt Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.50 |
| 52 Week High | US$1.56 |
| 52 Week Low | US$0.48 |
| Beta | 0.93 |
| 1 Month Change | -13.58% |
| 3 Month Change | -20.00% |
| 1 Year Change | -49.93% |
| 3 Year Change | -89.43% |
| 5 Year Change | n/a |
| Change since IPO | -98.44% |
Recent News & Updates
Recent updates
We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully
Nov 30
Little Excitement Around Bolt Biotherapeutics, Inc.'s (NASDAQ:BOLT) Revenues As Shares Take 29% Pounding
May 21We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully
Mar 15Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?
May 13Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?
Dec 01Bolt Biotherapeutics: A Promised Follow Up
Aug 26Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M
Aug 10We're Keeping An Eye On Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate
Jul 27We're Not Very Worried About Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate
Apr 12We Think Bolt Biotherapeutics (NASDAQ:BOLT) Can Afford To Drive Business Growth
Dec 03Bolt Biotherapeutics: Pioneering A New Class Of Immunotherapies
Aug 18We're Hopeful That Bolt Biotherapeutics (NASDAQ:BOLT) Will Use Its Cash Wisely
Aug 18Shareholder Returns
| BOLT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.3% | -3.6% | -2.4% |
| 1Y | -49.9% | -2.6% | 23.4% |
Return vs Industry: BOLT underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: BOLT underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| BOLT volatility | |
|---|---|
| BOLT Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BOLT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BOLT's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 100 | Willie Quinn | www.boltbio.com |
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer.
Bolt Biotherapeutics, Inc. Fundamentals Summary
| BOLT fundamental statistics | |
|---|---|
| Market cap | US$19.14m |
| Earnings (TTM) | -US$65.08m |
| Revenue (TTM) | US$9.78m |
2.0x
P/S Ratio-0.3x
P/E RatioIs BOLT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOLT income statement (TTM) | |
|---|---|
| Revenue | US$9.78m |
| Cost of Revenue | US$62.07m |
| Gross Profit | -US$52.29m |
| Other Expenses | US$12.80m |
| Earnings | -US$65.08m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.70 |
| Gross Margin | -534.72% |
| Net Profit Margin | -665.56% |
| Debt/Equity Ratio | 0% |
How did BOLT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 17:48 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bolt Biotherapeutics, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Schmidt | Guggenheim Securities, LLC |
| Edward White | H.C. Wainwright & Co. |
| Soumit Roy | JonesTrading Institutional Services, LLC |